
IRAKLIA Data Support Subcutaneous Isatuximab as a SOC Administration Approach in Myeloma
Isatuximab-irfc (Sarclisa) subcutaneous administration with an on-body delivery injector (OBI; Isa SC OBI) proved noninferior to intravenous administration (Isa IV), with the same levels of efficacy and pharmacokinetics (PK), comparable toxicity profiles, …